Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial - 01/09/21

Doi : 10.1016/S1470-2045(21)00376-4 
Johann S de Bono, ProfPhD a, , Niven Mehra, PhD b, Giorgio V Scagliotti, ProfMD d, Elena Castro, PhD e, Tanya Dorff, MD f, Adam Stirling, MD g, Arnulf Stenzl, ProfMD h, Mark T Fleming, MD i, Celestia S Higano, MD j, Fred Saad, MD k, Consuelo Buttigliero, PhD d, Inge M van Oort, PhD c, A Douglas Laird, PhD l, Marielena Mata, PhD l, Hsiang-Chun Chen, PhD l, Cynthia G Healy, BS m, Akos Czibere, MD n, Karim Fizazi, ProfMD o
a The Institute of Cancer Research and Royal Marsden Hospital, London, UK 
b Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands 
c Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands 
d Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy 
e Hospital Universitario Virgen de la Victoria and Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain 
f City of Hope Comprehensive Cancer Center, Duarte, CA, USA 
g ICON Cancer Centre, South Brisbane, QLD, Australia 
h Department of Urology, University Hospital Tübingen, Tübingen, Germany 
i Virginia Oncology Associates, US Oncology Research, Norfolk, VA, USA 
j University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA 
k Division of Urology, Centre Hospitalier de l’Université de Montréal (CHUM/CRCHUM), Montréal, QC, Canada 
l Pfizer, La Jolla, CA, USA 
m Pfizer, Collegeville, PA, USA 
n Pfizer, Cambridge, MA, USA 
o Institut Gustave Roussy, University of Paris Saclay, Villejuif, France 

* Correspondence to: Prof Johann S de Bono, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, London SM2 5NG, UK The Institute of Cancer Research and Royal Marsden Hospital Sutton London SM2 5NG UK



Poly(ADP-ribose) polymerase (PARP) inhibitors have antitumour activity against metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations in genes involved directly or indirectly in homologous recombination repair (HRR). In this study, we assessed the PARP inhibitor talazoparib in metastatic castration-resistant prostate cancers with DDR-HRR alterations.


In this open-label, phase 2 trial (TALAPRO-1), participants were recruited from 43 hospitals, cancer centres, and medical centres in Australia, Austria, Belgium, Brazil, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, South Korea, the UK, and the USA. Patients were eligible if they were men aged 18 years or older with progressive, metastatic, castration-resistant prostate cancers of adenocarcinoma histology, measurable soft-tissue disease (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]), an Eastern Cooperative Oncology Group performance status of 0–2, DDR-HRR gene alterations reported to sensitise to PARP inhibitors (ie, ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C), had received one or two taxane-based chemotherapy regimens for metastatic disease, and progressed on enzalutamide or abiraterone, or both, for metastatic castration-resistant prostate cancers. Eligible patients were given oral talazoparib (1 mg per day; or 0·75 mg per day in patients with moderate renal impairment) until disease progression, unacceptable toxicity, investigator decision, withdrawal of consent, or death. The primary endpoint was confirmed objective response rate, defined as best overall soft-tissue response of complete or partial response per RECIST 1.1, by blinded independent central review. The primary endpoint was assessed in patients who received study drug, had measurable soft-tissue disease, and had a gene alteration in one of the predefined DDR-HRR genes. Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT03148795, and is ongoing.


Between Oct 18, 2017, and March 20, 2020, 128 patients were enrolled, of whom 127 received at least one dose of talazoparib (safety population) and 104 had measurable soft-tissue disease (antitumour activity population). Data cutoff for this analysis was Sept 4, 2020. After a median follow-up of 16·4 months (IQR 11·1–22·1), the objective response rate was 29·8% (31 of 104 patients; 95% CI 21·2–39·6). The most common grade 3–4 treatment-emergent adverse events were anaemia (39 [31%] of 127 patients), thrombocytopenia (11 [9%]), and neutropenia (ten [8%]). Serious treatment-emergent adverse events were reported in 43 (34%) patients. There were no treatment-related deaths.


Talazoparib showed durable antitumour activity in men with advanced metastatic castration-resistant prostate cancers with DDR-HRR gene alterations who had been heavily pretreated. The favourable benefit–risk profile supports the study of talazoparib in larger, randomised clinical trials, including in patients with non-BRCA alterations.



Le texte complet de cet article est disponible en PDF.


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 9

P. 1250-1264 - septembre 2021 Retour au numéro
Article précédent Article précédent
  • Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
  • Tobias Nordström, Andrea Discacciati, Martin Bergman, Mark Clements, Markus Aly, Magnus Annerstedt, Axel Glaessgen, Stefan Carlsson, Fredrik Jäderling, Martin Eklund, Henrik Grönberg, STHLM3 study group, Carin Cavalli-Björkman, Astrid Björklund, Britt-Marie Hune, Mark Clements, Shuang Hao, Andrea Discacciati, Henrik Grönberg, Martin Eklund, Tobias Nordström, Stefan Carlsson, Markus Aly, Mats Walldén, Ola Steinberg, Karl Andersson, Fredrik Jäderling, Fredrik Wimmercranz, Edward Meurling, Axel Gleassgen, Nada Majeed, Rihab Awadelkarim, Ing-Marie Fyhr, Dag Sandström, Linda Waage, Otabek Imamov, Rafael Lantz, Andreas Thorstensson, Carl Stiernstedt, Dushaid Wande, Gunnar Trygg, Harald Söderbäck, Jerzy Michajlowski, Lars Leykamm, Nils-Erik Svedberg, Tommy Bergman, Raimundas Sabockis, Sirvan Akrawi, Martin Bergman, Magnus Annerstedt
| Article suivant Article suivant
  • Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
  • Xiaoxiang Zhou, Zhuoran Yao, Hua Bai, Jianchun Duan, Zhijie Wang, Xin Wang, Xue Zhang, Jiachen Xu, Kailun Fei, Zhen Zhang, Fengwei Tan, Qi Xue, Shugeng Gao, Yibo Gao, Jie Wang, Jie He

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.